TABLE 1.

Overall incidence of reactogenicity at the injection site after third vaccine dose^a

Group (n)	Incidence of symptomb
	Skin redness				Skin swelling				Muscle induration
	Preinjection	Dose 1	Dose 2	Dose 3	Preinjection	Dose 1	Dose 2	Dose 3	Preinjection	Dose 1	Dose 2	Dose 3
Control (5)	0.60 ± 0.25	0.80 ± 0.37	0.80 ± 0.20	0.80 ± 0.20	0.20 ± 0.20	0.20 ± 0.20	0.00 ± 0.00	0.00 ± 0.00	0.20 ± 0.20	0.12 ± 0.20	1.00 ± 0.32	0.20 ± 0.20
LSA1/AS01B (8)	0.25 ± 0.25	1.25 ± 0.31	0.63 ± 0.26	0.38 ± 0.26	0.13 ± 0.13	1.38 ± 0.26	0.63 ± 0.26	0.13 ± 0.13	0.00 ± 0.00	2.38 ± 0.18	1.88 ± 0.30	1.00 ± 0.27
RTS,S/AS01B (8)	0.38 ± 0.26	1.25 ± 0.31	0.88 ± 0.30	0.50 ± 0.19	0.25 ± 0.25	1.00 ± 0.38	0.75 ± 0.49	0.38 ± 0.38	0.00 ± 0.00	2.38 ± 0.18	2.00 ± 0.27	1.25 ± 0.31
LSA1/AS01B plus RTS,S/AS01B
LSA1 leg (8)	0.38 ± 0.18	1.13 ± 0.23	0.88 ± 0.30	0.63 ± 0.26	0.00 ± 0.00	1.38 ± 0.53	1.13 ± 0.44	0.13 ± 0.13	0.25 ± 0.16	2.63 ± 0.18	2.75 ± 0.16	2.00 ± 0.19
RTS,S leg (8)	0.38 ± 0.18	1.00 ± 0.27	0.88 ± 0.30	0.63 ± 0.26	0.00 ± 0.00	1.00 ± 0.38	1.13 ± 0.44	0.38 ± 0.26	0.00 ± 0.00	2.25 ± 0.31	2.38 ± 0.26	1.38 ± 0.18

^aGrade 3 muscle induration was frequently observed on days 1 and 2 after the third dose of vaccine. This subsided on day 3 and disappeared on day 14.

^bData are mean intensities ± SE for scores ranging from 0 to 3 (0, absent; 1, mild; 2, moderate; and 3, severe).